THE Australian Self Medication Industry (ASMI) has stated that consumers can have confidence in the safety profile and effectiveness of over-the counter (OTC) Proton Pump Inhibitors (PPIs) when they are used as recommended.
The industry peak body was responding to the publication of a recent study in the BMJ demonstrating a possible association between the use of prescription PPIs and a heightened risk of death (PD 05 Jul).
The observational study could only reveal an association but could not confirm a causal relationship.
ASMI Regulatory and Legal director Steve Scarff explained that the researchers admitted participants who were treated with prescription PPIs were older and therefore more likely to have other serious health conditions.
"OTC PPIs are used for the relief of frequent heartburn and are taken only for a shorter duration (up to 14 days) and usually at a lower dose than prescription PPIs," Scarff said.
"OTC PPIs are effective for the short-term management of gastro-oesophageal reflux disease, which is characterised by frequent heartburn.
"They should be used in accordance with the label directions and if consumers have any concerns they should discuss them with their healthcare professional."
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jul 17
